<DOC>
	<DOCNO>NCT01915108</DOCNO>
	<brief_summary>This study design determine optimal dose remifentanil prevent complication associate removal LMA without delay emergence .</brief_summary>
	<brief_title>Optimal Effect-site Concentration Remifentanil Inhibiting Response Laryngeal Mask Airway ( LMA ) Removal</brief_title>
	<detailed_description>Patients randomly assign one four group . All patient receive predetermined effect-site concentration ( Ce ) remifentanil target-controlled infusion ( TCI ) accord group assignment ( R0 , remifentanil Ce 0 ng/ml ; R0.5 , remifentanil Ce 0.5 ng/ml ; R1.0 , remifentanil Ce 1.0 ng/ml ; R1.5 , remifentanil Ce 1.5 ng/ml ) 10 minute end surgery LMA removal . Airway complication ( airway obstruction , desaturation , breath holding , cough ) , nausea , vomit assess emergence phase .</detailed_description>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>American Society Anesthesiologists physical status 1 2 undergo low extremity surgery general anesthesia suspect difficult airway respiratory disease ( chronic obstructive pulmonary disease , upper respiratory infection ) body mass index &gt; 30 kg/m2 allergy study drug history gastric reflux</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>